Tabelecleucel as an alternative treatment option in patients following transplantation

Dr. Prockop Discusses Tabelecleucel in Post-Transplant EBV+ LymphomasПодробнее

Tabelecleucel in the treatment of EBV+ PTLDПодробнее

Long-term outcomes of subjects with EBV driven PTLD following solid organ or allogeneic HCT trea...Подробнее

Clinical outcomes of patients with EBV-PTLD who fail rituximab following HSCTПодробнее

The role of transplantation in Ph+ ALL patients treated with chemotherapy-free regimensПодробнее

Strategies for the management of EBV-PTLDПодробнее

Update on ALLELE: tab-cel in patients with EBV+ PTLD following alloSCT after rituximab failureПодробнее

Tabelecleucel in EBV-associated PTLDПодробнее

Tab-cel for solid organ or allogeneic transplant recipients with EBV-PTLDПодробнее

The treatment and management of PTLDПодробнее

Liver Transplant Patient EducationПодробнее

Promising therapeutic efficacy of EBV-specific T-cell immunotherapy tabelecleucel in PTLDПодробнее

Atara BiotherapeuticsПодробнее

Tabelecleucel for treating EBV associated PTLDПодробнее

Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD)Подробнее

Is Stem Cell Transplantation Still a Treatment Option for Some DLBCL Patients?Подробнее

Advances in off-the-shelf third-party T-cells for the treatment of infectious diseases post-BMTПодробнее

Can we offer a curative treatment to transplant-ineligible R/R DLBCL patients?Подробнее

Study shows promise for virus specific T cell therapy following bone marrow transplantПодробнее